Long-termtreatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Y. E. Chung & S. H. Lee & S.-Y. Lee & S.-Y. Kim & H.-H. Kim & F. S. Mirza & S.-K. Lee & J. A. Lorenzo & G. S. Kim & J.-M. Koh
- چاپ و سال / کشور: 2011
Description
Summary We determined whether suppression of sclerostin levels by estrogen treatment was mediated by anti-resorptive effect. Raloxifene, but not bisphosphonates, suppressed circulating sclerostin concentration, suggesting that sclerostin may mediate the action of estrogen on bone metabolism, independently of their anti-resorptive effects. Introduction Circulating sclerostin concentrations are higher in postmenopausal than in premenopausal women, and estrogen treatment suppresses sclerostin levels in both men and women. We determined whether anti-resorptives may suppress the circulating sclerostin levels. Methods We conducted a retrospective observational study. Eighty postmenopausal women were treated with raloxifene for 19.4±7.7 months (n=16), bisphosphonates for 19.2± 6.7 months (n=32), or were untreated (n=32) for 17.1± 4.6 months. Plasma sclerostin concentrations were measured before and after treatment. Results Plasma sclerostin levels after treatment were significantly lower in the raloxifene than in the control group (55.8±23.4 pmol/l vs. 92.1±50.4 pmol/l, p=0.046), but were similar between the bisphosphonate and control groups. Relative to baseline, raloxifene treatment markedly reduced plasma sclerostin concentration (.40.7±22.8%, p<0.001), with respect to both control (.7.5±29.1%) and bisphosphonate (.3.1±35.2%) groups. Changes in bonespecific alkaline phosphatase and osteocalcin levels showed reverse associations with sclerostin concentration changes in the raloxifene (م=.0.505, p=0.017) and control (م=.0.410, p=0.020) groups. Conclusions Raloxifene, but not bisphosphonates, significantly suppressed circulating sclerostin concentration, suggesting that sclerostin may mediate the action of estrogen on bone metabolism, independently of their anti-resorptive effects.
Osteoporos Int DOI 10.1007/s00198-011-1675-1 Received: 22 December 2010 / Accepted: 4 May 2011
